Total assets have declined sharply from $13.0 million in 2024Q4 to $4.0 million in 2026Q1, reflecting a severe erosion of the equity base to $1.5 million.
| Total Current Assets | 2.09M | 3.94M | 10.82M | 1.21M | 1.47M | 1.05M |
| Cash & Short-Term Investments | 1.44M | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Cash Only | 1.44M | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 302.86K | 517.36K | 737.28K | 882.32K | 809.53K | 468.35K |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 342.55K | 382.89K | 363.79K | 264.76K | 101.14K | 30.19K |
| Total Non-Current Assets | 1.93M | 2.03M | 2.21M | 2.34M | 1.22M | 1.3M |
| Property, Plant & Equipment | 1.82M | 2.21M | 2.21M | 2.34M | 1.22M | 1.3M |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 105.2K | -176.77K | 0 | 0 | 0 | 0 |
| Total Assets | 4.02M | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Asset Turnover | 0.00x | - | - | - | - | - |
| Asset Growth % | 136.2% | -54.19% | 266.29% | 32.5% | 14.47% | - |
| Total Current Liabilities | 1.58M | 1.57M | 1.33M | 2.42M | 634.36K | 400.78K |
| Accounts Payable | 1.23M | 1.24M | 924.25K | 702.91K | 385.8K | 267.3K |
| Days Payables Outstanding | 107.79K | - | 1.26K | - | 953.06 | 1.64K |
| Short-Term Debt | 334.9K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 13.41K | 0 | 0 | 1M | 0 | 0 |
| Current Ratio | 1.32x | 2.51x | 8.12x | 0.50x | 2.32x | 2.61x |
| Quick Ratio | 1.32x | 2.51x | 8.12x | 0.50x | 2.32x | 2.61x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 908.36K | 1.01M | 1.28M | 1.53M | 678.77K | 748.25K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 3.86M | 917K | 1.16M | 1.39M | 463.77K | 587.14K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 90.36K | 123.58K | 0 | 0 | 0 |
| Total Liabilities | 2.49M | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Total Debt | 1.16M | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Net Debt | -279.68K | -1.8M | -8.33M | 1.55M | 50.2K | 172.82K |
| Debt / Equity | 0.76x | 0.37x | 0.13x | - | 0.44x | 0.60x |
| Debt / EBITDA | -0.12x | - | - | - | - | - |
| Net Debt / EBITDA | 0.03x | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 1.53M | 3.4M | 10.42M | -384.32K | 1.37M | 1.2M |
| Equity Growth % | 518.89% | -67.4% | 2811.49% | -128% | 14.66% | - |
| Book Value per Share | 0.18 | 0.41 | 1.28 | -0.05 | 0.17 | 0.15 |
| Total Shareholders' Equity | 1.53M | 3.4M | 10.42M | -384.32K | 1.37M | 1.2M |
| Common Stock | 8 | 8 | 8 | 6 | 6 | 12 |
| Retained Earnings | -23.47M | -21.1M | -11.95M | -6.08M | -4.05M | -2.65M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity exhaustion
As reported in financial statements, total assets have declined from $13.0 million in 2024Q4 to $4.0 million by 2026Q1, signaling a rapid depletion of the company's resource base as it struggles to achieve commercial viability while maintaining its specialized laboratory infrastructure.
The consistent contraction in total assets alongside a widening deficit in retained earnings suggests that the firm is consuming its capital base to fund ongoing R&D without a corresponding increase in productive capacity. Investors should monitor whether this downward trajectory in asset value reflects a strategic downsizing or an inability to secure the necessary capital to sustain operations.
According to recent SEC filings, the company's cash position has dwindled to $1.4 million as of 2026Q1, representing a significant reduction from the $9.7 million held in 2024Q4, which leaves the firm with a dangerously thin buffer against its ongoing operational burn rate.
The current ratio of 1.32, while technically above parity, masks the reality that the company lacks a sustainable revenue stream to replenish its cash reserves. This liquidity profile suggests that the firm may be forced into dilutive financing or emergency capital raises in the near term to avoid a total depletion of operating funds.
Based on the company's reported figures, equity has plummeted from $10.4 million in 2024Q4 to $1.5 million in 2026Q1, driven by persistent net losses that have pushed retained earnings to a deficit of $23.5 million, highlighting the severe erosion of shareholder value over the period.
The rapid decline in equity suggests that the company's business model is currently unable to generate sufficient value to offset its high fixed-cost structure. This trend warrants further investigation into whether the firm's reliance on equity-based funding will necessitate significant share dilution to keep the enterprise solvent.
While the balance sheet shows $1.8 million in net PPE as of 2026Q1, the lack of commercial revenue suggests these assets may be subject to future impairment charges if the SimplePath platform fails to transition from R&D to a revenue-generating commercial application.
The reliance on specialized laboratory equipment as a primary asset component creates a risk that the book value may not be recoverable in a liquidation scenario. Analysts should consider that the absence of goodwill on the balance sheet is a positive, yet it does not mitigate the fundamental risk that the firm's core technology may not hold long-term market value.
Quick answers to the most common questions about buying EXOZ stock.
As of 2025, eXoZymes, Inc. (EXOZ) had total assets of $6.0M including $3.9M in current assets.
eXoZymes, Inc. (EXOZ) carries total debt of $1.2M, offset by $3.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
eXoZymes, Inc. (EXOZ) has total shareholders' equity (book value) of $3.4M ($0.41 book value per share). Book value represents the net worth of the company belonging to common stock holders.
eXoZymes, Inc. (EXOZ) reported a current ratio of 2.51x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.